News &

Home 9 Dermapharm Corporate News 9 | Dermapharm continues to drive development of new products

| Dermapharm continues to drive development of new products


Corporate news

to the archive

Dermapharm continues to drive development of new products

  • New products for the treatment of acute hay fever symptoms open up significant market potential
  • bite away® successful in all distribution channels and receives award as one of the OTC growth champions

Grünwald, February 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil® and Momekort® in Germany just in time for the hay fever season. In addition, the patented medical product bite away® from the 2018 Hyperthermia range has performed well in all sales channels.

Since January 2019, Dermapharm has been offering the self-developed product Azedil® in Germany for treatment of acute hay fever problems in the eyes and nose. Azedil® is an antihistamine that is available individually as both a nasal spray and eye drops or in a combination pack. Dermapharm has also been offering Momekort®, a prescription-free nasal spray for adults that contains cortisone, for more severe symptoms caused by allergic symptoms of the nose since February 2019. The nasal spray has a local anti-allergic, anti-inflammatory and decongestant effect against hay fever symptoms. Momekort® has no sedative or habituation effect and can therefore be used throughout the entire hay fever season.

Due to the strong increase in allergies in the population, the demand for anti-allergic preparations is constantly growing(1). Just in time for the start of the main season for hay fever, which is usually from February to the end of July, Dermapharm has already stocked many pharmacies in Germany with the products Azedil® and Momekort®.

Dermapharm had already strengthened its OTC portfolio with the hyperthermal medical product bite away® at the end of 2017. The patented product is used for the symptomatic treatment of itching, pain and swelling caused by insect bites and stings. Since the acquisition of the technology, Dermapharm has been able to market bite away® very successfully in Germany and many other countries.

In 2018, the specialist magazine “HEALTHCARE MARKETING,” in cooperation with the market research institute “Insight Health,” has identified bite away® to be one of the fastest growing OTC products in pharmacies – offline and online. bite away has also developed very positively in other channels such as drugstores and e-commerce, occupying the top positions in the respective segments.

(1) European Centre for Allergy Research Foundation, Allergies – Facts and Figures, 2018.